Minocycline, a semisynthetic tetracycline derivative, protects brain against global and focal
ischemia in rodents. We examined whether minocycline reduces excitotoxicity in primary …

Minocycline, a semisynthetic second-generation tetracycline, was reported to have
neuroprotective effects in models of global and focal cerebral ischemia, the R6/2 mouse …

The neuroprotective effects of minocycline–which is broadly protective in neurologic-disease
models featuring cell death and is being evaluated in clinical trials–were investigated both in …

Minocycline ameliorates deficits in models of acute and chronic neurological diseases, but
many publications do not replicate these results. We tested the hypothesis that a key factor …

Several studies have shown that minocycline, a semisynthetic, second-generation
tetracycline derivative, is neuroprotective in animal models of central nervous system trauma …

Minocycline is a semisynthetic, tetracycline derivative that exerts anti‐inflammatory and
neuroprotective effects unrelated to its anti‐microbial action. We have previously shown that …

The lack of robust treatment options available for neurodegenerative diseases, stroke, and
central nervous system (CNS) trauma, all of which often involve both inflammation and …

Hypoxia is one of the important physiological stimuli that are often associated with a variety
of pathological states such as ischemia, respiratory diseases, and tumorigenesis. In the …

Activated microglia are implicated in the pathogenesis of disease‐, trauma‐and toxicant‐
induced damage to the CNS, and strategies to modulate microglial activation are gaining …

Initial studies conducted on the neuroprotective effects of minocycline, a second-generation
tetracycline, in experimental models of neurodegeneration gave promising results. However …